Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACT IV: Rindopepimut + GM-CSF with adjuvant temozolomide in newly diagnosed EGFRvIII-positive glioblastoma
2011-006068-32Phase 3Terminated
- Sponsor
- Celldex Therapeutics
- Start
- May 2012
- Modality
- Vaccines & Immunotherapeutics, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of rindopepimut in glioblastoma (GBM) (2 arms), sponsored by Celldex Therapeutics. Primary endpoint: Overall survival. Started May 2012; status: terminated.
02
Drugs
rindopepimut
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on 2011-006068-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-006068-32.